Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 15/20 | 1.00 |
| ▸ | CES2 | O00748 | 1/20 | 0.59 |
| ▸ | CES1 | P23141 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALAD | P13716 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15988671 | 0.83 | GSK3B (0.70) | GSK3BCES2CES1ALDH1A1LMNA | |
| SCHEMBL15282434 | 0.81 | GSK3B (0.68) | GSK3BCES2CES1ALDH1A1LMNA | |
| SCHEMBL6790693 | 0.79 | GSK3B (0.66) | GSK3BDAO | |
| SCHEMBL6789226 | 0.79 | GSK3B (1.00) | GSK3BALDH1A1DAO | |
| SCHEMBL553084 | 0.79 | GSK3B (0.66) | GSK3BCES2CES1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL26965167 | 0.78 | GSK3B (0.63) | GSK3BCES2CES1ALDH1A1LMNA | |
| SCHEMBL15979698 | 0.77 | GSK3B (0.62) | GSK3BCES2CES1ALDH1A1LMNA | |
| SCHEMBL23617480 | 0.76 | GSK3B (0.61) | GSK3BCES2CES1ALDH1A1LMNA | |
| SCHEMBL1032788 | 0.76 | — | — | |
| SCHEMBL27623970 | 0.75 | CES2 (0.73) | GSK3BCES2CES1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747057-B2 | SUCH 1-(2-BROMO-4,5-DICHLORO-THIOPHEN-3-YL)-2-CHLORO-ETHANONE FOR TREATMENT OF ALZHEIMER'S DISEASE OR DIABETES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2004-06-08 | — | — | US | disclosed |
| US-20030199508-A1 | Compounds and their therapeutic use | UNIVERSIDAD AUTONOMA DE MADRID (UAM) (ES) | 2003-10-23 | — | — | US | disclosed |
| WO-2003055479-A1 | COMPOUNDS AND THEIR THERAPEUTIC USE RELATED TO THE PHOSPHORYLATING ACTIVITY OF THE ENZYME GSK-3 | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199508-A1 | Compounds and their therapeutic use | CNKSR1, CBR1, CBR3 | GSK3B 4/4885CES2 215/4885CES1 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.